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Chlamydia
A Disease without a History
Michael Worboys
Since the late 1990s chlamydia has been the most commonly reported sex-
ually transmitted infection (STI) in Europe and the United States.1 The 
infection is caused by the bacterium Chlamydia trachomatis (C. trachoma-
tis), and its common name follows a pattern established in the late nine-
teenth century, where an infection is named after its causal pathogen.2 In 
England in 2017 there were just over 203,116 new diagnoses, compared to 
7,137 of syphilis and 44,676 of gonorrhea.3 Over 126,000 of the chlamydia 
diagnoses were made by the National Chlamydia Screening Programme, 
which targets fifteen to twenty-four-year-olds because the disease, which is 
asymptomatic in 80 percent of females infected, can lead to infertility due 
to blocked fallopian tubes. The disease has been equally prevalent in men, 
and while there has been an expectation of similar effects on seminal ves-
icles, there is as yet no evidence of a strong correlation between infection 
and male infertility.4 The program began in 2004, after a decade in which 
the reported incidence of chlamydia grew rapidly, and journalists picked up 
on these reports warnings of a “fertility timebomb.”5 Public health concern 
about the disease also derived from its seeming novelty and to uncertainties 
over its pathology. Chlamydia first became recognized as a specific STI in the 
1970s, but it took until 1988 for it to become notifiable. Newly diagnosed 
cases were reported only routinely in STI statistics from 1990, when there 
154 • chapter five
were 34,000 new diagnoses. The number began to rise steeply after 1995, 
reaching 100,000 in 2003. The growing incidence seemed to public health 
officials to be both “true” and “questionable.” The increase seemed to be true 
because of the increase in the number of couples seeking fertility treatment, 
plus the pattern of chlamydia’s spread seemed to fit with a view that young 
people were having a greater number of sexual partners.6 Yet it was also con-
sidered questionable because advances in treatments for infertility, notably in 
vitro fertilization, led to increased demand for services; also more and more 
cases of chlamydia were identified by improvements in the sensitivity and 
specificity of testing methods.
Chlamydia as an STI is a disease without a history in two senses: first, it 
became a clinical entity only in the 1970s, and, second, its medical and social 
history has still to be written—an absence this chapter begins to correct.7 
Its seeming novelty in the 1970s prompts the question, Was it an infection 
newly arrived in humans, or had it always been present and was now being 
recognized for the first time?8 This is a question that can only be answered, 
not by a medical historian but by investigations of past populations by epi-
demiologists, pathologists, and, perhaps most likely, by archaeologists using 
genomics. However, medical publications and oral testimony reveal that doc-
tors in the 1970s were confident that chlamydia was not a new disease. They 
believed this new ailment had actually been around for decades and probably 
centuries, being one, probably the most important, of the infections that had 
been hidden in that most unsatisfactory disease entity nongonococcal ure-
thritis (NGU), also called nonspecific urethritis (NSU). NGU was defined 
by what it was not. It required a laboratory diagnosis and had been invented 
by clinicians when, in patients with gonorrhea-like symptoms, the gono-
coccus could not be found in genital discharges. NGU was unaffected by 
antibiotics used to treat gonorrhea, which became further negative diagnos-
tic confirmation. The laboratory was also crucial to the creation of chlamydia 
as a clinical entity, which came from the development of new techniques 
in the 1960s and 1970s, which enabled doctors to differentiate NGU into 
component infections: C. trachomatis, lymphogranuloma venereum (LGV, 
which was later shown to be caused by different strains of C. trachomatis 
from those causing chlamydia), Mycoplasma genitalium, and trichomoniasis 
(caused by the protozoan Trichomonas vaginalis).9
While there is little or no historical scholarship on chlamydia as an STI, 
there are some studies of the bacterium’s other pathological effects, the eye 
infection trachoma, caused by the same bacterium; and psittacosis, a type 
of pneumonia caused by Chlamydia psittaci, which bird fanciers catch from 
infected animals.10 Trachoma is the leading cause of infectious blindness in 
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the world and now the subject of control efforts by several agencies.11 There 
are short histories of NGU, written by STI specialists, which discuss chla-
mydia along with the other diseases into which the entity has now been 
broken down; however, these tend to be presentist and teleological, por-
traying this differentiation as inevitable.12 The great challenge for historians 
writing the history of any disease, but especially one that is newly identified, 
is captured in Charles Rosenberg’s provocative claim that “a disease does not 
exist until we have agreed that it does, by perceiving, naming, and respond-
ing to it.”13 Or, as Peter Sedgwick put it, “There are no illnesses or diseases 
in nature”; rather, illnesses and diseases are the labels and action humans 
construct about the experiences, meanings, and implications of natural 
phenomena.14 Rosenberg qualifies the radical relativist implications of his 
statement by prefacing it with “in some ways” and applies it only to dis-
ease as a “social phenomenon.” His realist stance is clear in his view that 
disease is also a “biological event little modified by the particular context in 
which it occurs.”15 In this chapter I chart how the social and the biological 
were brought together by different historical actors to coproduce both NGU 
and chlamydia. For example, one distinctive feature of the biology of chla-
mydia—that it is largely symptomless in women—shaped social responses 
and clinical interventions, and these altered the epidemiology and perhaps 
the pathology of the infection. Indeed, STIs doctors since the 1990s have 
debated whether early antibiotic treatment has actually worsened the prob-
lem, leading to “arrested” immune responses and persistent vulnerability to 
infection.16
In this chapter I follow the more radical version of Rosenberg’s approach, 
with a narrative that details how chlamydia as a disease entity was constructed 
rather than discovered. I show how it was coproduced in the interactions 
of microbes, patients, doctors, scientists, public health agencies, and other 
actors, in the context of changing laboratory technologies, attitudes toward 
STIs and infertility, and health policies. My focus is on Britain, but the story 
was similar in other industrialized countries and increasingly internationally 
owing to shared research and comparisons of national policies. I begin with 
the construction of another clinical entity, nongonococcal urethritis, in the 
1930s, which, as the name indicates, was closely linked to medical and social 
ideas, practices, and policies for gonorrhea. A key difference was that NGU 
was framed as a condition that affected only men and, unlike gonorrhea, was 
not associated with ill health and sterility in women.17 NGU was unusual 
in being defined by what it was not and, for the time, in having its positive 
diagnosis dependent on laboratory testing.
156 • chapter five
I next consider medical and social responses to the growing incidence of 
NGU in men, from 1951, when new cases were first reported, to the early 
1970s. In Britain gonorrhea lost its status as the most prevalent venereal dis-
ease to NGU in 1975, prompting new interest in the latter. The incidence 
of chlamydia in women had been first reported in 1971 and soon became 
linked to infertility, pelvic inflammatory disease (PID), and chronic ill 
health. The manner in which chlamydia, as a component of NGU, changed 
from a one- to two-sex disease echoed how the pathology of gonorrhea was 
remade in the early twentieth century.18 My focus in this chapter is on the 
disease in women, but from the mid-1990s doctors reported that chlamydia 
could lead to infertility in men, albeit at a lower rate, by damaging sperm 
and causing epididymitis (and this has not since been confirmed).19 Finally, I 
discuss the changing profile of chlamydia from the mid-1970s to the 2010s, 
the key feature of which was the public health focus on the infection in 
women, reversing the previous situation. Its incidence in women became a 
major public health concern, and STI specialists and gynecologists began to 
talk about its role in creating an infertility crisis. The arrival of HIV/AIDS 
pushed these concerns aside until the late 1990s, when they were pushed to 
the fore again and once more linked to fertility and PID. Since then a num-
ber of initiatives have been developed to determine the level of incidence in 
young women, the most vulnerable group, and develop preventive and ther-
apeutic policies and programs.
Gonorrhea and Nongonococcal Urethritis, 1900–1945
Until the late nineteenth and early twentieth century, gonorrhea was a disease 
understood to affect mainly men. It was a specific type of urethritis, with a 
characteristic discharge from the penis and inflammation of the genitourinary 
system caused by the bacterium Neisseria gonorrhoeae. The infection typically 
“cleared up” in three or four weeks, though in many cases there were long-
term effects, the most common being inflammation of the joints. Gonorrhea 
was thought to be less common and less serious in women. However, doc-
tors were clear that women could harbor the gonococcus without symptoms, 
from the number of babies whose eyes were infected at birth and developed 
ophthalmia neonatorum, then a major cause of blindness.20 Some estimates 
are that a third of all blindness in the nineteenth-century era was due to 
this infection, a proportion that fell from the 1890s, when it became more 
common but by no means universal to irrigate the eyes of newborn babies 
with dilute silver nitrate.21 The medical and social recognition that gonorrhea 
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could be serious in women came from work of gynecologists and pathol-
ogists from the 1890s and the campaigning of public health doctors and 
women’s groups in the first decades of the twentieth century, with no one 
more active than Christabel Pankhurst. She set out her claims in The Great 
Scourge and How to End It, published in 1913, which is now best known for 
its seeming invitation for suffragists to start a “Sex War,” but it also had a 
lot to say about women’s health.22 The “Great Scourge” was venereal disease, 
but, unusually for the time, Pankhurst gave more space to gonorrhea than 
syphilis and special attention in a chapter on “The Dangers of Marriage.” She 
maintained that male doctors had concentrated on syphilis, the disease that 
affected mostly their sex, neglecting gonorrhea, the most serious venereal dis-
ease in women. Indeed, she stressed that men escaped lightly from gonorrhea 
with a short-lived, local infection, while women suffered long-term compli-
cations, children were threatened by blindness, and the race weakened by a 
falling birthrate, due to chronic ill health that led to women having fewer or 
no children.23 The principal consequence was salpingitis: “an attack of acute 
suppurating pelvic peritonitis with a background of genital symptoms due 
to acute suppuration of one or both Fallopian tubes.”24 In newly married 
women gynecologists termed it “honeymoon appendicitis,” but for those 
with the condition its consequences could be anything but short-term, with 
lifelong chronic ill health common. As Anne Hanley has shown, many doc-
tors linked venereal diseases with infertility, but there was no consensus on 
their importance or what to do.25 The aim of treatments, when tried, was to 
prevent the spread of the infection to the abdominal cavity (what would now 
be termed PID) and restore function to the fallopian tubes where possible, 
which often required surgery.
Contemporary medical opinion was that Pankhurst had exaggerated the 
incidence of gonorrhea, but that “the serious nature of the sequelae . . . is not 
exaggerated, and it is probably true that they are, on the whole, more serious 
in women than in men.”26 In the evidence given to the Royal Commission of 
Venereal Disease, doctors agreed that gonorrhea was responsible for around 
a third of all sterility, affecting both men and women. Similar estimates of 
the impact of gonorrhea could be found in the other industrialized coun-
tries.27 In his book on Gonorrhea in Women, published in 1913, the US 
gynecologist Charles Norris reported “that 30 per cent, to 50 per cent, of all 
childless marriages are directly caused by gonorrhoea.”28 Interestingly, some 
doctors suggested that the by then relative rarity of ophthalmia neonatorum 
in obstetric practice was as much due to (increased) female sterility produced 
by gonorrhea as much as it was to disinfection of babies’ eyes.29 Through the 
1920s and 1930s medical views on infection and sterility divided on gender 
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lines: the condition in men was linked primarily to epididymitis caused by 
gonorrhea, while in women it was associated with infection of the cervix, 
salpingitis, and pelvic inflammation, as well as puerperal sepsis.30 In fact, the 
gonococcus was not the only pathogen associated with sterility: staphylococci, 
streptococci, the tubercle bacillus, and as yet unspecified microorganisms 
such as viruses (first identified in this period) were also all implicated. In 
1937 Maeve Kenny, who worked at Queen Charlotte’s Maternity Hospital, 
Hammersmith, published an article on the aftereffects of puerperal infec-
tion.31 Her study was of a hundred women treated in the isolation block of 
Queen Charlotte’s, and her principal finding was “that sterility is a promi-
nent sequel to puerperal infection,” though she could only speculate on how 
the disease affected women’s reproductive organs and fertility.
Kenny had pioneered, with Leonard Colebrook, the introduction of sul-
fonamide drugs, which were transforming the prognosis of women with 
puerperal sepsis and impacting maternal mortality.32 Sulfonamides also 
transformed the treatment of gonorrhea.33 The sex of the patients in the 
early trials is rarely mentioned, but the implication is that they were prin-
cipally men, as success was judged by the absence of clinical symptoms.34 
The improvement in the treatment of gonorrhea, along with the prognoses 
for patients with syphilis, due to Salvarsan and its derivatives, meant that at 
the end of the 1930s doctors were more and more challenged by patients 
with chronic, nonspecific venereal disease and its effects. In a letter to the 
Lancet in September 1937, A. Malcolm Simpson argued, “It seems obvious 
that the syphilis department of a V.D. clinic should be divorced from the 
gonorrhoeal one; the director of the former having special experience in der-
matology, cardiology, and neurology, and that of the latter in genito-urinary 
surgery and gynaecology.”35
The particular success of sulfonamides in the treatment of gonorrhea 
revealed the number of patients at venereal disease clinics who had “geni-
to-urinary (non-gonococcal) infections.”36 Arthur Harkness, a South African 
who had qualified at Guy’s Hospital in 1914 and then served in the Royal 
Navy Reserve, had labeled this a disease entity in 1933.37 Harkness’s NGU 
diagnosis depended on negative bacteriological results from patients with 
the symptoms of gonorrhea, a group that sulfonamide treatment further dif-
ferentiated.38 Apparently, Harkness found NGU only in men, with women 
mentioned only as sources of male infection; indeed, its sex specificity was 
another marker of NGU’s distinctiveness from gonorrhea.39
The first published exploration of a link between NGU and trachoma was 
in 1939, in a review by Lawrence Harrison, Britain’s leading venereologist; 
and Werner Worms, a German émigré doctor.40 Their focus was on “Waelsch 
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urethritis,” a type of urethritis first identified in 1901, and on the presence 
of so-called inclusion bodies in a number of inflammatory venereal condi-
tions: trachoma, inclusion blennorrhoea, various types of conjunctivitis, 
LGV, and NGU. Trachoma had attracted the attention of ophthalmologists 
in the 1920s, with the International Organization against Trachoma founded 
in 1930.41 The agency was created around two appeals: first, the preven-
tion of blindness in infants and, second, halting its spread from the tropics; 
indeed, trachoma had been made a notifiable disease in Glasgow in 1914 
because of fears of its importation.42 At its meeting in 1935, the organiza-
tion’s president maintained that its work “may deservedly be placed among 
the campaigns against cancer and tuberculosis.”43 There was agreement 
among ophthalmologists that trachoma was infectious and was associated 
with intracellular or inclusion bodies that had been first observed in 1907 by 
Ludwig Halberstaedter and Stanilaus von Prowazek. These became known 
as TRIC agents (from trachoma inclusion conjunctivitis), and their presence 
within cells (intracellular) led many bacteriologists to place them in the new 
category of viruses; but there were other possibilities: phagocytosed gono-
cocci or rickettsia—intracellular bacterial pathogens.44 Around 1930 similar 
inclusion bodies were reported in cases of psittacosis, a disease of birds that 
had spread to humans in sporadic outbreaks in the 1920s and early 1930s.45
In the 1940s textbooks on venereal diseases began to include a chapter 
on “Other Conditions.” Angus McLachlan’s Handbook of Diagnosis and 
Treatment of Venereal Diseases, published in 1944, discussed eight such dis-
eases: balanoposthitis, LGV, NGU, thrush, trichomoniasis, ulcus actum 
vulvae, vaginitis, vulvovaginitis, and warts. He wrote that the most puzzling 
was NGU, which he also termed “simple urethritis” and “post-gonococcal 
urethritis” (PGU).46 Clinicians suggested three causes; typically, each was 
morally loaded: (1) septic and opportunistic bacterial infection, linked to 
sodomy or intercourse during menstruation; (2) chemical irritation due to 
the use of contraceptives; and (3) physical trauma caused by sexual excess.47 
The idea that women were carriers and the primary source of the infection 
was implied in 1942 by Gerald McElligott, a Royal Air Force medical offi-
cer, when he wrote, after a survey of men, that “I have not recently had the 
opportunity of examining many female consorts.” Nonetheless, he suggested 
that infection from women was likely to be facilitated by previous venereal 
infection; unclean and careless methods of douching; the growing use of 
internal menstrual tampons; and previous instrumental interference with the 
cervix, in other words, induced abortion.48
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NGU Established, 1945–1975
Investigations of NGU had flourished during World War II because of the 
attention given to venereal diseases in the armed services and the success of 
sulfonamides and then penicillin in treating gonorrhea.49 In January 1948 
the first report of the newly formed World Health Organization’s Expert 
Committee on Venereal Diseases drew attention to a number of genitouri-
nary infections of “ill-defined origin,” including NGU, and called for more 
studies of them.50 The findings were based mostly on evidence submitted by 
Harkness, which showed that NGU was common worldwide. Two years later 
Harkness published a book titled Non-gonococcal Urethritis, which reviewed 
the literature on all manner of genitourinary conditions and concluded 
that NGU was a specific condition, though one for which he was unable to 
specify a microbial cause or diagnostic test.51 He mentioned C. trachomatis 
as a possible factor, though he was unclear whether it was a primary cause, 
secondary consequence, or coincidental contaminant. Harkness’s work was 
largely behind the inclusion of NGU in British statistics of new cases of 
venereal disease from 1951.52
In 1954 Harkness and Claude Nicol, the author of a standard textbook on 
venereal diseases, spoke on NGU at a joint meeting of the Medical Society 
for the Study of Venereal Diseases and of the Metropolitan Branch, Society 
of Medical Officers of Health.53 The discussion after their talk revealed that 
doctors remained dissatisfied with accounts of NGU’s causation but agreed 
that bacteria were likely the primary or secondary pathogens, given that the 
new mycin-based antibiotics cured nearly 90 percent of cases. However, a 
review in the British Journal of Venereal Diseases the following year identi-
fied four infective candidates as the cause of NGU—bacteria, viruses (which 
would have included TRIC agents), pleuropneumonia-like organisms 
(PPLO), and trichomonads—or that it was non-infective and a primary 
prostate disorder. They concluded that “infection is the probable cause but 
has not been proved for the majority of cases.” The authors also discussed 
diagnosis and treatment, typically constructing NGU by exclusion: “(1) 
Whereas gonorrhoea is promptly cured by penicillin, leaving a negligible 
number of relapses, the position is different with [NGU,] where treatment is 
less specific, and relapses are common. . . . (2) The diagnosis of gonorrhoea 
in the male is straightforward, but that of [NGU] depends on negative prop-
erties and is thus less easily definable.”54 Despite the uncertainties and the 
variety of terms and categories, figures for the reported incidence of NGU 
continued to be published in annual venereal disease statistics.
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When the disease was first reported in 1951, there were 10,764 cases in 
men; unsurprisingly, no numbers for women were given.55 That year there 
were 14,975 new cases of gonorrhea in men and 3,089 in women. The gon-
orrhea figures for women were known to be underestimates for two reasons: 
clinics tended to test only the contacts of infected men, and the infection 
was known to be often symptomless in women. Diagnosis of NGU still 
followed the two negatives: the absence of gonococci and non-responsive-
ness to penicillin. An investigation into the aetiology, published in 1954, 
which considered just men, did mention women as “consorts” but admitted 
defeat in identifying any specific “virus” for NGU. However, immunological 
tests suggested that links with LGV, psittacosis, and cat-scratch fever mer-
ited further attention.56 In about three-quarters of cases, NGU responded 
to treatment with antibiotics such as chloramphenicol, aureomycin, terra-
mycin, and erythromycin.57 The reported incidence of new cases of NGU in 
men rose steadily through the 1950s, such that in 1961 there were 24,472 
new cases, against 29,519 of gonorrhea.58
In a lecture on “Venereal Disease and Public Health” in 1960, McElligott, 
who had risen to be adviser in venereal diseases to the Ministry of Health, 
reflected on the new epidemiological picture of venereal diseases: “Today 
gonorrhoea and, indeed, early syphilis, promptly and properly treated .  .  . 
still have a cure rate of not much less than 100%. Our therapeutic problems 
now for the most part comprise relapsing NGU in men with its occasional 
complications, and trichomoniasis in women patients, the latter condition 
being increasingly sent on to us by our gynaecological colleagues.”59
He worried too about social attitudes to NGU because, “not being a stat-
utory venereal disease,” it had been “neglected by the public and the medical 
profession alike, and is often regarded as a respectable complaint rather than 
a dirty disease with disgraceful implications.”60 The incidence of new cases 
of NGU exceeded those for gonorrhea for the first time in 1965, and this 
spurred greater interest into the condition among venereologists. Ideas on 
causation were fixed firmly on microorganisms.
In the 1964 edition of their textbook on venereal diseases, Ambrose King 
and Claude Nicol noted several possibilities: TRIC agents; mycoplasma, or 
bacteria without cell walls, like those that caused pleuropneumonia (termed 
pleuropneumonia-like organisms or PPLOs); Trichomonas vaginalis; fungi; 
and a Haemophilus influenza organism.61 The idea that NGU was an aller-
gic reaction of some type was also mentioned. However, the predominant 
view was that it was an infection, and the possibility of a link between tra-
choma and NGU was behind work undertaken by Eric Dunlop, with the 
Oculogenital Virus group at the Institute of Ophthalmology at Moorfields 
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Eye Hospital.62 Nonetheless, the nature of the microorganism remained 
uncertain, as was only too clear in an article on NGU in the Lancet in 
1965, in which the authors stated they had been studying “a member of the 
Bedsonia or psittacosis/lymphogranuloma/TRIC group.”63 Bedsonia is now 
often regarded as an obsolete term for the Chlamydia group of microorgan-
isms.64 The review concluded with suggestions of new names for NGUs in 
men and, seemingly for the first time, in women: “TRIC agent urethritis” 
and “TRIC agent cervicitis.”65
It was not until 1971 that the number of new cases of NGU in women 
was reported in the annual reports of the chief medical officer in Britain. 
It had been previously discussed in clinical publications but had not been 
officially recorded because it was “not a clear-cut clinical entity.”66 However, 
cases had been included in “other conditions” requiring treatment within 
the [VD] center, in which now remained LGV, trichomoniasis, candidiasis, 
scabies, pubic lice, genital herpes, genital warts, genital molluscum and other 
treponomal diseases.67 The exclusion of chlamydia from the list of “other 
sexually transmitted diseases” indicated that doctors had decided that it 
belonged with NGU.
The figures for 1971 were 14,418 new NGU cases in women compared to 
62,498 in men, with population rates of 56.54 per 100,000 in women and 
263.55 in men. The report observed,
Research on the causative agent or agents in this group continues to be sup-
ported by the DHSS and MRC. It is encouraging that at least four centres are 
now investigating the role of Chlamydia group A organisms in this condition. 
However, it is still reasonable to suspect that other infective agents are impli-
cated and the possibility that there may be pathogenic strains of mycoplasma 
cannot be discarded; their isolation in the upper genital tract in women with 
pelvic complications has been reported from Sweden. The diagnosis of infec-
tion in female sex contacts remains a difficult problem, but their diagnosis and 
treatment seems indicated when there is evidence of inflammatory changes in 
the genito-urinary tract.68
There was discussion of the “epidemiological” or “blind” treatment of 
“consorts”—that is, giving antibiotics to asymptomatic women contacts 
of male sufferers with the aim of preventing the reinfection of men and, 
secondarily, treating women. This indicated that women were still seen 
as vectors rather than sufferers of NGU. The women’s health movement 
of the 1960s was dependent on established, mostly male, STD specialists 
and initially focused on the “venereal diseases” of syphilis and gonorrhea.69 
However, this changed in the 1970s; for example, the 1973 edition of Our 
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Bodies, Ourselves included information on “other non-categorized sexually 
transmitted diseases,” but it was not until the 1980s that discussion of the 
triad of chlamydia, PID, and infertility was added.70
Chlamydia: In Fashion Again?
In 1974 a review article in the Lancet on chlamydia began with the statement: 
“The Chlamydia genus is in fashion again.”71 The previous occasion alluded 
to was work on trachoma, but the new attention was because of evidence of 
its role in genital infection and PID. The article was prompted by the inves-
tigations that were finding a “considerable proportion [up to 45 percent] of 
‘non-specific’ genital infection is due to Chlamydia.”72 There was similar evi-
dence from the United States, where a study of 113 men with NGU showed 
42 tested positive for C. trachomatis and commented that “the cause of chla-
mydia-negative NGU . . . remains obscure.”73 The reference to “‘non-specific’ 
genital infection” reflected a shift in terminology as NGU was replaced by 
NSGI or the more common NSU, which I use from now on. In Britain 
the key researcher was Eric Dunlop, who is now remembered as “the person 
who first put chlamydial genital infection in the medical and general public 
domain”; this was work published in 1972.74 He was an ophthalmologist, 
and his suggestion that C. trachomatis was a cause of pelvic inflammatory 
disease came from observations of the number of mothers, whose babies had 
chlamydial ophthalmia neonatorum, suffered from salpingitis.75
In the 1975 edition of their textbook, King and Nicol still listed seven 
possible causal agents of NSU but were confident that “Chlamydia-subgroup 
A is, at any rate, one cause of non-specific urethritis.”76 In the same year a 
study based on patients at Guy’s Hospital in London concluded that only 20 
percent were “truly non-specific”; the remainder broke down as follows: chla-
mydia, 40 percent; mycoplasma, 20 percent; trichomoniasis, 15 percent; and 
candidiasis, 5 percent.77 The diversity of diseases making up NSU remained 
a challenge and, according to Robbie Morton, a venereologist based in 
Sheffield, “In spite of much laboratory and other research, nonspecific gen-
ital infection continues to be the venereologist’s most perplexing problem, 
clinically, diagnostically and therapeutically.”78 In 1978, Michael Adler, then 
at the Middlesex Hospital and following a review of the diagnosis and report-
ing of NSU, wrote, “It is extremely unsatisfactory that when the disease is 
discussed, described, diagnosed, and notified no accepted criteria are in exis-
tence” and “The commonest diagnosis made in STD clinics [is] the one with 
the least uniformity.”79 The difficulties in diagnosis were acknowledged in the 
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reports of the chief medical officer, where it was noted that “in the absence of 
specific diagnostic tests outside the research field, therapy remains empirical 
and the possibilities of control are therefore less than in other sexually trans-
mitted diseases.”80
The tests in the “research field” first used cultures grown in hen’s eggs and 
then less cumbersome techniques with McCoy cells.81 Laboratory diagnostic 
tests began by measuring anti-Chlamydial antibodies using serological meth-
ods.82 At this time there were well established and relatively inexpensive tests 
for the main STDs: serology with the Wassermann reaction for syphilis and 
culturing and microscopy for gonorrhea. Chlamydiae, like viruses, live inside 
cells not in the intracellular matrix; hence, their manipulation in the labora-
tory required the same techniques and materials as those for viruses. Relative 
to the new methods, cell culturing was technically demanding, time con-
suming, expensive, and difficult to standardize. It was beyond the capacity of 
most public health and clinical microbiology laboratories. Adler’s survey of 
diagnostic methods being used in the late 1970s revealed that most clinicians 
were using microscopy to examine urethral exudates, which were stained and 
then examined for polynucleated leukocytes—a nonspecific test where the 
presence of this type of white blood cell is taken as an indicator of an infec-
tion.83 Such deficiencies led to calls for the development of better testing 
and the creation of a cell culture service to enable accurate diagnosis of the 
most common STD.84 In Britain the new diagnostic techniques and new 
interest in chlamydia led to studies of women attending STD clinics and an 
association with promiscuity.85 A study in Manchester, published in 1977, 
used the new methods and found Chlamydia organisms in 26 percent of the 
“promiscuous women” attending the Special Clinic and 1 percent among the 
control “non-promiscuous group”; the latter was in fact “two hundred female 
members of hospital staff.” The authors were still cautious about the status 
of chlamydia as a cause of STDs but worried that “in this investigation, 
Chlamydia were isolated from 20% of asymptomatic females, indicating 
the possibility of a considerable potential reservoir of infection.”86 Why was 
this concerning? Principally, concerns were growing about the link between 
STDs and infertility, as seen in an editorial in the British Medical Journal in 
1975, titled “Promiscuity and Infertility,” which focused on tubal inflamma-
tion caused by gonorrhea.87
Two wider changes in STDs in the late 1970s and early 1980s impacted 
the emergence of chlamydia as an important public health problem: HIV/
AIDS and the medicalization of infertility. I will not go into these in any 
detail, as there is a large, now historical, literature on each, though, inter-
estingly, chlamydia is rarely mentioned, if at all.88 First and most important 
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was HIV/AIDS, which radically altered the profile of STDs in medicine and 
wider society, and the “safe sex” message led to a reported decline in new cases 
of chlamydia infection in women.89 One consequence was that STD services 
expanded and were better funded, with greater investment in diagnostic ser-
vices and expertise in viral diseases. Closely related, there was the creation of 
the new specialism of genitourinary medicine.90 GUM clinics replaced the 
still stigmatized venereal diseases or STD departments and tried to normal-
ize STDs by dealing with them alongside other diseases of the reproductive 
and excretory systems. Second, there was the medicalization of infertility and 
the development of in vitro fertilization.91 Among many new approaches, 
doctors sought ways to correct or circumvent blocked fallopian tubes, which 
in turn drew attention to the possibilities of prevention, through the early 
recognition of the factors causing salpingitis and other infections of cervix, 
uterus, and abdomen.
Infection and Infertility
In the late 1970s medical attention on infection and infertility was focused 
on intrauterine contraceptive devices as major causes of ectopic pregnancies, 
salpingitis, and PID.92 Pelvic inflammation in women had been recognized 
since the late nineteenth century, but PID as a clinical entity was constructed 
in the 1960s, first in relation to septic infection and then to STDs. These 
links were central to the controversy over the Dalkon Shield, an intrauterine 
contraceptive device associated with a high incidence of internal injuries and 
infections in its users and perhaps infertility.93 The leading work on the link 
between infection and infertility focused on salpingitis—inflammation and 
obstruction of the fallopian tubes. The leading researchers were in depart-
ments of obstetrics and gynecology, such as Lars Weström at the University 
Hospital in Lund, Sweden, and with the WHO Collaborating Centre for 
Reference and Research on Trachoma and Other Chlamydial Infections. As 
early as 1975, they reported a study of 415 women followed over nine and 
half years: “Tubal occlusion was diagnosed after one infection in 12.8 per 
cent, after two infections in 35.5 per cent, and after three or more infections 
in 75 per cent of the women. Tubal occlusion was more common after non-
gonorrheal than after gonorrhoeal salpingitis.”94 In 1980 Weström reported 
on the long-term effects of PID and recent changes: “The prevalence of 
women in the post-PID state has increased by a factor of about 1.5 since 
1960. Women in the post-PID state have a tenfold increased risk for ectopic 
pregnancy and 25% of the increase in ectopic pregnancy can be accounted 
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for by the increase in post-PID women.” The overall picture was alarming: 
“Infertility after PID ranges between 5.8% and 60% depending on severity 
of infection, number of infections, and age of the woman. The fraction of 
women rendered infertile because of PID has increased by a factor of about 
1.6 since 1960.”95
An indication of the new medical importance being given to PID was a 
meeting in April 1980 of an International Symposium at the Centers for 
Disease Control in Atlanta solely on the condition.96 James Curran of CDC 
explained the problem:
Pelvic inflammatory disease is the most common serious complication of sexu-
ally transmitted infections caused by Neisseria gonorrhoeae and Chlamydia tra-
chomatis. If PID and ectopic pregnancy rates continue unabated, by the year 
2000 there will have been more than one episode of PID and three related 
physician visits for every two women who reached reproductive age in 1970. 
Fifteen per cent will require hospitalization, more than 3% will experience 
an ectopic pregnancy, and more than 10% will involuntarily become sterile 
because of PID.97
Michael Adler, E. H. Belsey, and B. H. O’Connor, from a more limited 
study than Weström, drew less alarmist conclusions. They focused on gon-
orrhea and the overall morbidity rather than infertility. However, they noted 
that the incidence of PID in England and Wales had risen “only” 50 percent 
between 1968 and 1977, and this would have impacted fertility.98 A direct 
linkage between chlamydia, PID, and infertility was first aired by Duncan 
Catterall in an article in the Lancet in February 1981 titled “Biological 
Effects of Sexual Freedom”:
The radical changes in attitudes to sex and in sexual behaviour during the 
past 25 years have resulted in a sustained increase in the incidence of STD. 
Research has led to the recognition of a new generation of STDs many of 
which cause pelvic inflammatory disease and sterility. Inability to become 
pregnant usually, leads to frustration and unhappiness, and treatment is often 
unsuccessful. The new generation of STDs has serious and potentially danger-
ous effects on expectant mothers and their babies. Damage to the developing 
tissues can occur in the uterus, infection may be transmitted at birth, or the 
infant may develop disease during the first few months of life. Their effects 
on prematurity, birth weight, early rupture of the membranes, and failure to 
thrive are only just being investigated, and there may be some surprises. The 
adverse biological effects of sexual freedom on women and their babies are a 
disappointing development in the second half of the 20th century.99
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Catterall expected that chlamydia, rather than gonorrhea, as previously 
thought, was the major cause of PID and ectopic pregnancies.100 He worried 
further that the true level of the chlamydia infection and that of other “new” 
pathogens was unknown, because, “unfortunately, laboratory facilities are 
totally inadequate and thousands of cases are unrecognised.”101 However, he 
was concerned there was a major problem of fertility decline in the making.
In their large volume on Disease and Fertility (1984), Joseph McFalls and 
Marguerite McFalls, had separate chapters for NGU and “genital chlamydia” 
and for the latter detailed experimental and clinical evidence of salpingitis 
due to chlamydia-impairing conception.102 A research study published in 
1984, using the new method of measuring antibodies rather than cell cul-
ture, also found strong indications of C. trachomatis infection in 75 percent 
of women with damaged fallopian tubes, compared with 31 percent of sev-
enty-five infertile women with normal fallopian tubes.103 High-antibody 
levels were found in 15 percent of fertile women. The authors concluded that 
tests for the microorganism “should routinely be part of infertility investiga-
tions.”104 There was support from the new GUM specialists about the scale 
of the problem, evidenced by the increasing number of ectopic pregnancies, 
and for wider testing.105 In the same year a review in the Journal of Obstetrics 
and Gynaecology on “Chlamydia trachomatis infections and their importance 
to the gynaecologist” ended by warning of the “tragic sequelae,” citing pro-
jections from the United States:
By the year 2000, two out of every three women who had reached reproduc-
tive age in 1970 will have had one bout of pelvic inflammatory disease and as 
a result visited their doctors or sexually transmitted disease clinics three times. 
Fifteen per cent of this group will have been hospitalised for treatment of pel-
vic inflammatory disease and of these, one-half will require surgery. Curran 
(1980) estimates that if one episode of pelvic inflammatory disease confers a 
20 per cent chance of infertility then 10 per cent of women in this reproduc-
tive age group will have been sterilised by pelvic inflammatory disease alone.106
Such apocalyptic warnings diminished through the 1980s, and it is not 
clear why. One likely factor is that the interests and work of GUM specialists 
and researchers shifted to HIV/AIDS, where an even greater public health 
crisis was foreseen.107 Also, the improved success rate and availability of in 
vitro fertilization meant that tubal damage or obstruction was no longer an 
untreatable cause of infertility. Nonetheless, investigations of the incidence of 
chlamydia infection continued to be made. A study published in 1991 tested 
swabs from a cervical cancer–screening clinic in Glasgow and found 6–12 
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percent positive, while a study of all women referred in Lothian by general 
practitioners to GUM clinics found the microorganism in 3.5 percent of 
samples tested.108 In both reports the authors claimed that the incidence was 
high; though they acknowledged that the number of these infections that led 
to PID and infertility remained unknown, the implication was that clinical 
experience pointed to a connection.
Chlamydia: The More You Look the More You Find
In principle there are two methods of diagnosing an infection: either to iso-
late and identify the actual pathogen by microscopy or culture methods, or 
to find a proxy indicator of its presence. In the latter case this might be either 
a marker from the microorganism (a toxin, membrane protein, or genetic 
material) termed an antigen or a marker from the immune response of the 
person infected, typically an antibody. The constructed character of such 
methods was explored in Ludwig Fleck’s classic study of syphilis.109 The diffi-
culties in microscopical identification of its bacterial cause—the Trepanoma 
pallida—led doctors to explore methods that tested the blood serum of the 
patient for antigens and antibodies. Fleck showed how the accepted method, 
the Wassermann reaction, was changed from “measuring” antigens to anti-
bodies and, though standardized, produced results that varied between 
laboratories, influenced by materials, skills, and the meanings attached to 
results. For example, it was a matter of judgment whether the degree to 
which a run of tests gave few false positives (a result that indicates that a 
given condition is present when it is not) or false negatives (a result that indi-
cates that a given condition is absent when it is present). Nonetheless, Fleck 
showed that the Wassermann reaction, a laboratory test, became as, if not 
more, important than clinical signs and symptoms in making the diagnosis 
of syphilis a “fact.” The importance of the Wassermann reaction to venere-
ologists meant that they were early adopters, compared to other specialisms, 
in relying on the laboratory. This was nowhere clearer than with the con-
struction of NGU in the 1930s as the absence of the gonococcus, which was 
possible because of the routinization of bacteriological investigations in vene-
real disease clinics, and this has also been the case with chlamydia.
Three ways of diagnosing chlamydia infection were developed: utilizing 
cell culture, identifying antigens in blood and urine samples, and identify-
ing antibodies in blood. The earliest, cell culturing, was the “gold standard” 
because the actual organism was “seen,” though this required making it vis-
ible by staining and fixing, procedures that were demanding, lengthy, and 
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expensive. And, as clinicians had effective antibiotics at hand, their practice 
was to treat first and then, maybe or maybe not, confirm the diagnosis. Cell 
culturing was highly specific, but there were questions about its sensitivity 
and accuracy. Specificity, sensitivity, and reliability are key terms in bacte-
riological testing. Specificity refers to the degree to which a test identifies 
only a particular microorganism and not other members of the genus or 
related bacteria. Sensitivity refers to the probability of actually detecting the 
specific organism, though how this is judged depends on the assumed gold 
standard for 100 percent detection. Accuracy relates to sensitivity, in rela-
tion to the overall percentage of false positives and false negatives but also 
to the precision and replicability of the test, not least its independence from 
the equipment and skill levels of technicians in different laboratories and at 
different times.
Culture methods were improved in the 1970s, first, with the use of 
irradiated McCoy cells allowing culturing to be standardized. Second, iden-
tification was improved when traditional chemical stains were replaced by 
fluorescently labeled antibodies that adhered to the bacillus, allowing rapid 
and specific identification through a microscope with ultraviolet light.110 This 
method, developed first for trachoma and LGV, was nearly 100 percent spe-
cific, though its laboratory sensitivity was estimated at only 70–85 percent 
and overall sensitivity lower, at 40–85 percent, due to sampling errors and 
variable laboratory standards.111 There remained the question of the qual-
ity of the samples tested: might microorganisms have been missed in taking 
swabs, urine, and blood samples or died between clinic and laboratory?
In the 1980s there was a return to vogue of microscopical identification 
without culturing, using a technique known as direct fluorescence assay. 
The test involved attaching specially manufactured antibodies to specific 
sites on the outer membrane of Chlamydia. Specimens taken from the ure-
thra and reproductive organs were allowed to react with antibodies, which 
also carried luminescence-labeled reagents. After washing, the sample was 
examined for any antibodies remaining adhered to microorganisms, with 
clinical pathologists looking for bright spots, typically green, under ultravi-
olet light. When compared with other methods results were more variable, 
influenced by many factors, including the recognition that were three 
strains or serotypes of C. trachomatis. Nonetheless, it was used because it 
was quick and relatively inexpensive.
Advances in molecular biology, many developed by the new biotech-
nology companies and using monoclonal antibodies, revolutionized 
the laboratory diagnosis of all diseases, and chlamydia was no excep-
tion.112 There were new tests for antibodies (complement fixation and a 
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microimmunofluorescence) and new antigen tests (direct fluorescence assay 
and enzyme immunoassay).113 There was intense competition between the 
companies producing the tests, as the demand for diagnostic testing and, 
later, screening for chlamydia grew. Manufacturers made competing claims 
for specificity, sensitivity, and accuracy, as well as price and speed. All were 
compared to the gold standard of cell culture, though there were increas-
ing doubts that this was any better than any of the new tests.114 It was a 
difficult argument to settle, as the different tests were testing for different 
things; nonetheless, the public health authorities in England and Wales had 
sufficient confidence to include new cases of chlamydia in the STI statistics 
from 1990.
In the 1990s new tests became available that used the new DNA tech-
nologies, most notably the polymerase chain reaction technologies, to 
develop nucleic acid amplification tests (NAATs).115 In these tests frag-
ments of Chlamydia DNA extracted from clinical samples were duplicated 
in repeating cycles, to produce samples large enough for colorimetric eval-
uations. The first such test was introduced by Roche in 1993—Amplicor C. 
trachomatis. The following year an evaluation made by doctors in Bordeaux 
found that it had a sensitivity of 95.3 percent and a specificity of 100 per-
cent and concluded that it was superior to culture methods.116 Other tests 
from other companies followed: the ligase chain reaction from Abbott 
Laboratories Illinois and transcription mediated amplification from Gen-
Probe, La Jolla, California. A review of the new tests found that while they 
were based on different molecular strategies, they had equivalent specific-
ity and sensitivity to Roche Amplicor.117 In a review in 1998 interestingly 
titled “Chlamydia trachomatis: The More You Look the More You Find; 
How Much Is There?,” Julius Schachter suggested it was time to abandon 
the old assumptions:
There has been a revolution in diagnostic methodology in recent years with 
the introduction of nucleic acid amplification tests (NAAT). These tests are 
far more sensitive than any of the earlier nonculture tests. For the first time, 
diagnostic laboratories have a technology that is more sensitive than isolation 
in tissue culture (TC). TC, which has long been considered the gold standard 
for diagnosis of C. trachomatis, is recognized as having a specificity approach-
ing 100% but is considered to be less sensitive, with estimates typically being 
on the order of 75% to 85% sensitivity in expert laboratories. The NAAT have 
shown that these estimates of the sensitivity of cell culture are overestimates. 
There is even a wider variability in the performance of culture from laboratory 
to laboratory, than had been previously surmised.
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The new methods had, he argued, completely changed the landscape.
The nonculture methods led to broad-based testing for C. trachomatis and 
changed chlamydia diagnostics from being a cottage industry into being on the 
regular public health laboratory menu. But these tests were even less sensitive 
than culture. The NAAT offered tests that were more sensitive than culture. 
We became aware that the estimates of prevalence of infection determined in 
the past by either TC [tissue culture] or early nonculture tests (antigen detec-
tion methods or the direct nucleic acid probes) were gross underestimates. 
The number of infections detected by nucleic acid amplification tests could 
be higher by up to 80% as compared with the use of the older technology.118
The improvement offered by the new DNA-based techniques were indi-
cated in a study published in 1997, where the older enzyme immunoassay 
methods found a prevalence of 1.6 percent (0.8 to 2.7 percent), with a sen-
sitivity of 60 percent and a specificity of 100 percent, while the ligase chain 
reaction found 2.5 percent (1.5 to 3.9 percent), with 90 percent sensitivity 
and 99.8 percent specificity. Not only did the new technologies offer greater 
specificity, sensitivity, and accuracy; they were cheaper and easier. Hence, it 
became possible to move beyond diagnostic testing to screening for symp-
tomless chlamydia infection in both men and women. Paradoxically, the 
NAAT technologies may have been responsible for the continuing increase 
in reported new cases, as they enabled more tests to be made and with greater 
sensitivity.119
The possibility of large-scale screening became policy in Britain in 1998, 
when the government accepted the recommendation of the chief medical 
officer’s Expert Advisory Group’s report on Chlamydia trachomatis that a 
pilot trial be made.120 Two groups were tested systematically: women and 
men attending GUM clinics and women seeking termination of pregnancy; 
there was also to be opportunistic screening of sexually active women aged 
under twenty-five, especially teenagers. Why make the trial? First, there was 
the rising annual rate of new cases of chlamydia, which reached fifty thou-
sand in 1998–99, over three times that for gonorrhea; and, second, so much 
infection is asymptomatic, and, untreated, its consequences for women were 
severe and lifelong and had implications for society at large. An editorial in 
the British Medical Journal welcomed the report and stressed the importance 
of its recommendations. “The role of chlamydia in infertility is well docu-
mented: the disease may be implicated in as much as 50% of cases. Many 
cases of infertility occur in the absence of clinical pelvic inflammatory dis-
ease, and when this disease process occurs is unknown. A reduction of the 
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incidence of chlamydia infection in the community may therefore produce a 
corresponding fall in the related incidence of infertility.”121
Pilot studies showed high rates—10 percent infected—among young 
women attending general practitioners and other clinics.122 This prompted 
the establishment in September 2002 of the National Chlamydia Screening 
Programme, by which time new chlamydia cases each year was approaching 
a hundred thousand. The program “offered” screening to all women and men 
under twenty-five years of age attending various clinical setting using NAATs. 
The technical term for this type of screening was “opportunistic”—that is, 
it was offered, but it was up to patients whether to accept and to practi-
tioners how strongly, if at all, they encouraged participation. Nonetheless, 
in the first year over 16,000 samples were tested (15,241 women and 1,172 
men). Excluding those seen at GUM clinics and assumed to represent the 
general population of young adults, the program found “chlamydia positiv-
ity among people under 25 years of age screened in non-GUM settings was 
10.1% (1538/15,241) in women and 13.3% (156/1172) in men.”123 Views 
on the program were mixed. Some doctors complained that it was hardly 
a public health measure as long as screening remained opportunistic. The 
participation of general practitioners was optional and not incentivized; few 
men were screened and contacts untraced.124 On the other side there were 
questions about its cost-effectiveness, in part because of new views on the 
natural history of the infection:
Increasing evidence shows that the rate of progression of endocervical chla-
mydia to pelvic inflammatory disease is lower than previously thought. 
Population based studies consistently estimate lower incidence rates of pel-
vic inflammatory disease than clinic-based studies. Infections detected by 
screening asymptomatic people might therefore have a better prognosis than 
symptomatic infections, because of differences in the burden of the organism. 
Descriptions of chlamydial infection and its consequences, and models of the 
impact of screening, however, nearly always cite the higher estimates.125
It was, of course, unsurprising that those who were promoting screening 
used the data that supported their case, but equally interesting was the redef-
inition of the problem to be tackling pelvic inflammatory disease rather than 
infertility. This change may have been due to the impact of gender politics, 
considering women’s health as such, rather than in terms of motherhood, 
and the impact of in vitro fertilization, but it also reflected less confidence 
in the extent to which chlamydia is a direct and major cause of infertility. 
This is borne out by later assessments. A Cochrane Review published in 2013 
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found the following: “In women, chlamydia ascends to the upper genital 
tract in approximately 10% of cases to cause symptomatic pelvic inflam-
matory disease (PID). The resulting tubal damage can then cause ectopic 
pregnancy, tubal infertility and chronic pelvic pain. Although about 45% of 
tubal infertility might be attributable to chlamydia infection, the probability 
of tubal infertility in women who have had chlamydia is estimated to be only 
1% to 4%.”126
The range of these population estimates is very wide, and such uncer-
tainties mean that how, and to what extent, C. trachomatis infection causes 
infertility has remained a subject of intense research. A 2015 study of the 
subject concluded, after discussing the complex interactions of host, immu-
nological, epidemiological, and pathogen factors, that “the actual process 
of host and pathogen factors that result in infertility remain uncertain and 
require further investigation.”127
From Male NGU to Female Chlamydia
Chlamydia as an STI was constructed medically and socially from the 
breakup of NGU as a clinical entity in the 1970s. There was no eureka 
moment. Rather, there was a slow buildup of evidence, from laboratory 
investigations using the new tools of molecular biology, that NGU—which 
had become an embarrassment to STI specialists as a catch-all, negative 
diagnosis—was a number of distinct infections. Given that my approach 
followed Rosenberg’s maxim that “a disease does not exist until we have 
agreed that it does, by perceiving, naming, and responding to it,” it might 
be thought inconsistent that I begin with discussion of the construction of 
NGU in the 1930s. Does this mean my history is presentist and teleological 
in assuming that chlamydia was always present in NGU? In part, yes: all 
history is a dialogue between the present and the past, and we cannot escape 
our knowledge of the deconstruction of NGU in component parts from the 
1970s. But also, no: I discuss the emergence of NGU in its historical context 
as a disease entity in its own right, not as a mistaken, temporary entity whose 
demise was inevitable. NGU was modeled as having symptoms like gonor-
rhea, but also unlike it in not being caused by the gonococcus. However, 
there was another largely unremarked difference. Venereologists found no 
place for female disease in the new infection, which leads to questioning how 
well integrated into their practice was concern about the extent and serious-
ness of gonorrhea in women shown by gynecologists and pathologists, and 
championed by the suffragettes, in the early twentieth century. The maleness 
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of NGU was further enshrined by the work of venereal disease services in 
World War II and medical and social attitudes that saw women as only con-
sorts and contacts.
NGU attracted increased attention in the 1970s from STD specialists and 
researchers because of its increased incidence and continuing dissatisfaction 
with its uncertain causes. The application of cell culture techniques made 
possible the isolation of C. trachomatis from patients with GNU. This new 
modeling of the disease made it similar in aetiology and pathology to gonor-
rhea, which led clinicians to ask about the consequences of the infection in 
women more generally. The link between chlamydia and PID was well estab-
lished by the early 1980s, specifically to salpingitis and ectopic pregnancies. 
This coincided with new medical interventions and social concern about 
infertility, which led to the reconstruction of chlamydia as a female disease, 
as seen in the development of screening programs targeted at women. This 
was not in terms of incidence—it was assumed to be equal in both sexes—
but, because it was symptomatic in men, it was treatable, whereas in women 
symptomless, untreated infection was linked to infertility and PID. The main 
prompt for this reconstruction was the rising incidence of new cases of chla-
mydia in young women and projections of the long-term effects of untreated 
or repeat infection over childbearing years. The association between chla-
mydia, infertility, and PID proved to be powerful in mobilizing public 
health initiatives. However, these programs have come under scrutiny for 
their cost-effectiveness—future benefits in fertility and cost savings remain 
projections and easy targets for cuts. Furthermore, while no one doubts that 
chlamydia is a factor in infection-induced infertility, there continue to be 
ambivalent findings on how, and to what extent, C. trachomatis infection is a 
direct cause of infertility.
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